Rodop is revolutionizing cancer treatment
The unsolved crisis
Long-term survival rates for many aggressive solid tumors—including cancers of the brain, lung, stomach, esophagus, and pancreas—have barely improved since the 1970s. For patients diagnosed with stage IV disease, the prognosis remains grim, with nearly 95% mortality within five years.
The main reason cancers like these remain so deadly is that chemotherapy drugs fail to reach cancer cells uniformly within solid tumors. When chemotherapy doesn’t fully eliminate cancer cells, those cells survive, adapt, and eventually cause the cancer to return, making effective treatment increasingly challenging.
Introducing ChemoDrivers
ChemoDrivers are a new class of therapeutic agents designed to overcome the biggest limitation in cancer treatment: getting chemotherapy drugs directly into solid tumors. Unlike conventional methods, ChemoDrivers enhance the penetration and accumulation of existing chemotherapy drugs deep within tumors. They achieve this by actively remodeling the tumor environment, breaking down physical and biological barriers that currently prevent effective drug delivery. The result is more chemotherapy reaching cancer cells at therapeutically effective doses, significantly improving treatment outcomes without increasing toxicity.
Transforming chemotherapy into personalized medicine
ChemoDrivers are poised to transform chemotherapy into truly personalized medicine. Our vision is to integrate ChemoDrivers with advanced single-cell tumor sequencing to precisely map each patient’s cancer biology. Rodop’s novel in vitro assays will rapidly identify the most effective combination of ChemoDriver and chemotherapy drug tailored to individual tumors. This targeted approach will ensure optimal treatment choices from day one, increasing effectiveness, reducing recurrence, and redefining patient outcomes in cancer therapy.
Our Team
